


PHARMACEUTICAL 2021

Adicet Bio Inc. Rank 135 of 409







PHARMACEUTICAL 2021

Adicet Bio Inc. Rank 135 of 409



The relative strengths and weaknesses of Adicet Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Adicet Bio Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Adicet Bio Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is -28%, being 326% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	100,336
Cost of Goods Sold	0
Intangible Assets	20,089
Liabilities, Current	22,479
Liabilities, Non-Current	20,424
Other Assets	30,620
Other Compr. Net Income	1.0
Other Expenses	-2,681
Other Liabilities	1,105
Other Net Income	-953
Property and Equipment	2,790
Research and Development	34,334
Revenues	18,688
Selling, General and Administrative Expense	22,760

Output Variable	Value in 1000 USD
Assets	153,835
Liabilities	44,008
Expenses	54,413
Stockholders Equity	109,827
Net Income	-36,678
Comprehensive Net Income	-36,678
Economic Capital Ratio	-28%